Top-down versus step-up approach after endoscopic ultrasound-guided drainage of infected walled-off necrosis: a randomized controlled trial.

EndoscopyJun 1, 2026 (epub)
Clinical ResearchGastroenterology

Sanish Ancil, Jimil Shah, Vaneet Jearth et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared top-down versus step-up approaches after endoscopic ultrasound-guided drainage of infected walled-off necrosis in 54 patients. The top-down group required fewer reinterventions (1 vs. 2; P = 0.02) and had lower readmission rates (18.5% vs. 44.4%; P = 0.04), indicating a potential advantage in clinical outcomes.

Key findings

  • Top-down approach resulted in fewer reinterventions (1 vs. 2; P = 0.02).
  • Readmission rates were significantly lower in the top-down group (18.5% vs. 44.4%; P = 0.04).
  • Length of stay was shorter in the top-down group (4 days vs. 12 days; P <0.001).
  • New-onset organ failure and procedure-related adverse events were similar across both groups.

Why it matters

Understanding the optimal approach for managing infected walled-off necrosis can improve patient outcomes, reduce hospital stays, and minimize readmissions, which are critical factors in gastroenterology practice.

Source

Published in Endoscopy. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.